OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
OS Therapies IncorporatedAMEX: OSTX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $10.04M rose 100.9% year over year, behind the +199.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 15.3% from the prior quarter. Over 3 fiscal years it compounded at +85.4% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +100.9% toward the trailing-twelve-month pace of +199.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 28.34M USD
- Year-over-year change
- +316.1%
- 4-year CAGR
- +66.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.34M | +316.1% |
| FY2024 | 2024-12-31 | 6.81M | +56.8% |
| FY2023 | 2023-12-31 | 4.34M | -2.3% |
| FY2022 | 2022-12-31 | 4.45M | +20.9% |
| FY2021 | 2021-12-31 | 3.68M | — |
Operating Expenses vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 operating expenses of $33.51M is the 5th highest of the 9 companies compared; the peer median is $27.15M.
- Its year-over-year change of +199.7% is the highest of 8, against a peer median of -22.3%.
- Over three fiscal years its annual growth of +85.4% compares with a peer median of -25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Jun 2026 | $43.72M | -39.4% | -5.5% | 208.2% | |
| LTM Jun 2024 | $36.55M | — | -32.2% | 4480.0% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| LTM Mar 2026 | $12.67M | +38.6% | -26.4% | — | |
| Peer median (excluding OSTX) | $27.15M | -22.3% | -25.9% | 999.7% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.16M | 805 | 4.22K | 2.78K | 363.09K |
| Gross Profit | (1.16M) | (805) | (4.22K) | (2.78K) | (363.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.17M | 3.29M | 3.22M | 2.84M | 16.36B |
| Selling, General & Admin | 1.5M | 1.15M | 1.12M | 3.97M | 12.34B |
| Operating Expenses | 3.68M | 4.45M | 4.34M | 6.81M | 28.34M |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09K |
| EBITDA | (4.84M) | (4.45M) | (4.34M) | (6.83M) | (28.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.84M) | (4.45M) | (4.34M) | (6.81M) | (28.71M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 249 |
| Interest Expense | 2.58M | 1.81M | 3.45M | 2.05M | 0 |
| Other Income / Expenses | (2.58M) | (1.81M) | (3.45M) | (2.07M) | (48.14K) |
| Income Before Tax | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| EPS (Diluted) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| Weighted Avg Shares | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
| Weighted Avg Shares (Diluted) | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.